KR102569226B1 - 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 - Google Patents

운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 Download PDF

Info

Publication number
KR102569226B1
KR102569226B1 KR1020177012838A KR20177012838A KR102569226B1 KR 102569226 B1 KR102569226 B1 KR 102569226B1 KR 1020177012838 A KR1020177012838 A KR 1020177012838A KR 20177012838 A KR20177012838 A KR 20177012838A KR 102569226 B1 KR102569226 B1 KR 102569226B1
Authority
KR
South Korea
Prior art keywords
atoms
group
formula
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177012838A
Other languages
English (en)
Korean (ko)
Other versions
KR20170082532A (ko
Inventor
헨리 조셉 브레슬린
오렌 길라드
Original Assignee
아트린 파마슈티컬스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아트린 파마슈티컬스 엘엘씨 filed Critical 아트린 파마슈티컬스 엘엘씨
Publication of KR20170082532A publication Critical patent/KR20170082532A/ko
Application granted granted Critical
Publication of KR102569226B1 publication Critical patent/KR102569226B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
KR1020177012838A 2014-10-13 2015-10-13 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 Active KR102569226B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462063176P 2014-10-13 2014-10-13
US62/063,176 2014-10-13
US201562104274P 2015-01-16 2015-01-16
US62/104,274 2015-01-16
PCT/US2015/055317 WO2016061097A1 (en) 2014-10-13 2015-10-13 Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors

Publications (2)

Publication Number Publication Date
KR20170082532A KR20170082532A (ko) 2017-07-14
KR102569226B1 true KR102569226B1 (ko) 2023-08-22

Family

ID=55654998

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177012838A Active KR102569226B1 (ko) 2014-10-13 2015-10-13 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제

Country Status (12)

Country Link
US (3) US9663535B2 (enExample)
EP (1) EP3207031B1 (enExample)
JP (1) JP6678679B2 (enExample)
KR (1) KR102569226B1 (enExample)
CN (1) CN107108527B (enExample)
AU (1) AU2015333738B2 (enExample)
BR (1) BR112017007708B8 (enExample)
CA (1) CA2963973C (enExample)
ES (1) ES2879441T3 (enExample)
IL (1) IL251595B (enExample)
MX (1) MX389198B (enExample)
WO (1) WO2016061097A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017007708B8 (pt) 2014-10-13 2023-10-24 Atrin Pharmaceuticals LLC Composto macrocíclico e composição farmacêutica
WO2017180723A1 (en) * 2016-04-12 2017-10-19 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
EP3630116B1 (en) 2017-05-26 2024-05-01 The Board Of Regents Of The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
SMT202400106T1 (it) 2017-07-13 2024-05-14 Univ Texas Inibitori eterociclici della atr chinasi
EP3668839B1 (en) 2017-08-17 2023-04-12 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
WO2019055657A1 (en) * 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University BAF COMPLEX MODULATION COMPOUNDS AND METHODS OF USE
CN112218631B (zh) 2018-03-16 2023-12-22 德州大学系统董事会 Atr激酶的杂环抑制剂
CN110357905B (zh) * 2018-03-26 2021-10-01 武汉誉祥医药科技有限公司 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途
EP3820460A1 (en) 2018-07-12 2021-05-19 The Board of Trustees of the Leland Stanford Junior University Methods for reversing hiv latency using baf complex modulating compounds
CN110950890B (zh) * 2018-09-27 2022-07-01 北京赛林泰医药技术有限公司 取代的咪唑并[4,5-c]喹啉大环化合物作为多靶点激酶抑制剂
MX2021005012A (es) 2018-10-30 2021-07-21 Repare Therapeutics Inc Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr.
CN114369096A (zh) 2020-10-16 2022-04-19 上海迪诺医药科技有限公司 三杂环衍生物、其药物组合物及应用
WO2023201320A1 (en) 2022-04-14 2023-10-19 Atrin Pharmaceuticals LLC Atr inhibitors
CN119317434A (zh) 2022-06-15 2025-01-14 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
WO2025181153A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with pi3k alpha inhibitors
WO2025229051A1 (en) 2024-05-03 2025-11-06 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with antiandrogen agent
WO2025233224A1 (en) 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with anti-pd(l)1 therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071837A1 (en) 2008-12-19 2010-06-24 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230098B2 (en) * 2003-02-26 2007-06-12 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
US7163939B2 (en) * 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
JP2013526540A (ja) * 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2012125603A1 (en) * 2011-03-16 2012-09-20 Cephalon, Inc. Macrocyclic compounds as alk, fak and jak2 inhibitors
ES2621220T3 (es) * 2012-03-06 2017-07-03 Pfizer Inc. Derivados macrocíclicos para el tratamiento de enfermedades proliferativas
WO2013139697A1 (en) * 2012-03-17 2013-09-26 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
BR112017007708B8 (pt) 2014-10-13 2023-10-24 Atrin Pharmaceuticals LLC Composto macrocíclico e composição farmacêutica

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071837A1 (en) 2008-12-19 2010-06-24 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase

Also Published As

Publication number Publication date
JP6678679B2 (ja) 2020-04-08
BR112017007708A2 (pt) 2017-12-19
BR112017007708A8 (enExample) 2017-12-19
KR20170082532A (ko) 2017-07-14
WO2016061097A1 (en) 2016-04-21
MX2017004515A (es) 2017-10-31
US9981989B2 (en) 2018-05-29
IL251595A0 (en) 2017-06-29
ES2879441T3 (es) 2021-11-22
EP3207031A4 (en) 2018-02-14
BR112017007708B1 (pt) 2023-07-25
AU2015333738A1 (en) 2017-05-04
US20170226130A1 (en) 2017-08-10
CN107108527A (zh) 2017-08-29
US9663535B2 (en) 2017-05-30
US20160102104A1 (en) 2016-04-14
CA2963973A1 (en) 2016-04-21
AU2015333738B2 (en) 2020-03-26
CN107108527B (zh) 2022-08-02
MX389198B (es) 2025-03-20
JP2017531041A (ja) 2017-10-19
EP3207031B1 (en) 2021-04-14
BR112017007708B8 (pt) 2023-10-24
EP3207031A1 (en) 2017-08-23
IL251595B (en) 2022-04-01
CA2963973C (en) 2023-01-10
US10196405B2 (en) 2019-02-05
US20180230168A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
KR102569226B1 (ko) 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제
TWI827646B (zh) Ptpn11抑制劑
CA2969090C (en) Triazolopyrimidine compounds and uses thereof
CN107922431B (zh) Hpk1抑制剂及其使用方法
JP5389785B2 (ja) キナーゼ阻害剤として有用なチアゾールおよびピラゾール
KR20130129244A (ko) 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도
WO2018031680A1 (en) Novel compounds, uses and methods for their preparation
EP3472161B1 (en) Triazolopyridine compounds and uses thereof
JP2016512816A (ja) Ａｔｒキナーゼの阻害剤として有用な化合物
JP2013526540A (ja) Ａｔｒキナーゼ阻害剤として有用な化合物
JP2016512815A (ja) Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
CA2785923A1 (en) Therapeutic compounds and related methods of use
JP2010528021A (ja) キナーゼのインヒビターとして有用なチアゾールおよびピラゾール
JP2010524962A (ja) オーロラキナーゼ阻害剤のための創薬法
CA3163389A1 (en) Biphenyl derivative inhibitor, preparation method therefor and use thereof
CN104725249A (zh) 苄胺类衍生物及其在药物上的应用
JP2016540773A (ja) Ａｔｒキナーゼの阻害剤として有用な化合物
CN108558833B (zh) 吡唑醇类化合物、其药物组合物及其在药物中的应用
KR20170067299A (ko) 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
JP2014530202A (ja) コリンキナーゼ阻害剤として有用な化合物
HK1235837B (en) Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
HK1235837A1 (en) Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
HK40057478A (en) Hpk1 inhibitors and methods of using same
TW201629071A (zh) 稠合雜環化合物
CN109988171A (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170512

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201012

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221208

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230502

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221208

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230502

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230208

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201012

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20230620

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20230613

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230502

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230208

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201012

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230817

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230818

End annual number: 3

Start annual number: 1

PG1601 Publication of registration